Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Schering-Plough reports earnings

SGP reported second quarter EPS of $0.02, excluding special charges, which beat

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE